AstraZeneca (AZN) Receives Buy Rating from JPMorgan Chase & Co.

JPMorgan Chase & Co. reaffirmed their buy rating on shares of AstraZeneca (LON:AZN) in a research note released on Friday.

A number of other equities research analysts have also commented on the company. Barclays reaffirmed an overweight rating on shares of AstraZeneca in a research report on Tuesday, October 9th. Shore Capital reaffirmed a hold rating on shares of AstraZeneca in a research report on Friday, September 7th. Jefferies Financial Group reaffirmed a hold rating and set a GBX 5,800 ($75.79) price target on shares of AstraZeneca in a research report on Friday, October 12th. Credit Suisse Group set a GBX 6,350 ($82.97) price target on AstraZeneca and gave the stock a buy rating in a research report on Thursday, August 30th. Finally, Citigroup reaffirmed a buy rating and set a GBX 6,200 ($81.01) price target on shares of AstraZeneca in a research report on Tuesday, September 25th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of Hold and a consensus price target of GBX 5,831.89 ($76.20).

Shares of LON AZN traded up GBX 79 ($1.03) during mid-day trading on Friday, reaching GBX 6,172 ($80.65). 2,861,442 shares of the company’s stock were exchanged, compared to its average volume of 2,310,000. AstraZeneca has a twelve month low of GBX 4,260 ($55.66) and a twelve month high of GBX 5,520 ($72.13).

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Recommended Story: Trading Strategy Methods and Types

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply